Transfection Technologies Market

Transfection Technologies Market by Product (Kits, Equipment), Method (Physical (Electroporation, Microinjection), Biochemical (Lipofection, Calcium Phosphate), Viral), Application (Biomedical Research, Therapeutic Delivery) & Region - Global Forecast to 2028

Report Code: BT 1355 Feb, 2024, by marketsandmarkets.com

The global transfection technologies market in terms of revenue was estimated to be worth $1.2 Billion in 2023 and is poised to reach $1.8 Billion by 2028, growing at a CAGR of 9.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of the market is largely driven by the increased R&D investments and growing need of cell-based therapies. Furthermore, increased research activities for drug discovery and development, the transfection technologies have seen substantial expansion over the last decade.

Transfection Technologies Market - Global Forecast To 2028

Transfection  Technologies Market

To know about the assumptions considered for the study, Request for Free Sample Report

Attractive Opportunities in the Transfection Technologies Market

Transfection  Technologies Market

Global Transfection Technologies Market Dynamics

DRIVER: Growing demand for cell & gene therapy

Cell and gene therapies are advanced therapies used to treat a wide range of diseases such as cancer, cystic fibrosis, heart disease, and genetic disorders. Cell therapy is referred to a therapy in which viable cells are injected or implanted into patient’s body to get therapeutic effects. On the other hand, gene therapy is the medical technology used to produce therapeutic effect through manipulation of gene expressions. Thus, cell and gene therapies are widely used for the treatment of genetic and rare diseases. The adoption of cell & gene therapy has increased over the last few years, and this trend is expected to continue in the coming years due to the high and rising incidence of cancer and other rare diseases. For instance, to data released by GLOBOCAN in 2020, it was estimated that 19.3 million cases new cancer cases and 10.0 million cancer deaths occurred in 2020. The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020. Therefore, increasing need of cell & gene therapy due to rising prevalence of chronic diseases is propelling the growth of market.

RESTRAINT: Limited efficiency of transfection technologies

Transfection technologies have wide range of applications in biomedical research, therapeutic delivery, cell and gene therapy, and protein production. However, the common causes of transfection failure are decreased transfection efficiency and decreased cell viability. Low transection efficiency of the transfection technology is associated with various factors such as low DNA concentration, contaminants in culture medium, mechanical damage to the cells, and DNA degradation. . Additionally, low cell density and contaminated DNA leads to low cell viability. Thus, limited efficiency of transfection methods might hamper the growth of market.

OPPORTUNITY: Increasing focus on personalized medicine

Transfection technologies are used to deliver foreign material into eukaryotic cells to produce personalized medicine. Personalized medicine aims to provide tailored medical treatment for chronic, degenerative, and genetic disorders. Increasing focus on personalized medicines drives the growth of market. Government bodies are focusing on the development of advanced personalized medicines. For instance, the regulatory authorities approve diagnostics and therapeutics for use as personalized medicine. In 2022, the FDA approved 12 personalized medications, representing approximately 34% of all newly approved therapeutic molecular entities.

CHALLENGE: Concern related to the cytotoxicity and transfection in hard-to-transfect cells

The transfection of cells can cause cytotoxicity resulting to prevention of growth and proliferation of cells, leading to cell death. The cellular toxicity caused by transfection is influenced by the reagent and the nature of the cells. A higher transfection rate is generally associated with increased toxicity. Therefore, concern related to cytotoxicity and transfection of hard-to-transfect cells is one of the major challenges for the growth of the market.

Global Transfection Technologies Industry Ecosystem Analysis

The ecosystem of market consists of end users from pharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and others, transfection technologies product providers, instrument & reagent suppliers, technology providers, regulatory authorities (ensuring compliance and safety), and collaborative networks promoting knowledge sharing and collaboration. These stakeholders interact and collaborate to drive the advancement of transfection technologies products, enhance drug discovery processes, and develop new therapeutics.

Transfection  Technologies Market Ecosystem

Physical transfection held a dominant share in the method segment in the transfection technologies industry.

Based on the method, the transfection technologies market has been segmented into physical transfection, biochemical transfection, and viral vector transfection. In 2022, physical transfection accounted for the largest share of the market. This is attributed to the high adoption of the technologically advanced transfection method. In addition, growing demand for safe and efficient transfection methods is promoting the growth of market. The rising adoption of rapid cell transfection methods is supporting the market growth.

The therapeutic delivery segment of transfection technologies industry is expected to register fastest growth during the forecast period.

Based on the application of transfection technologies market, the market has been segmented into biomedical research, therapeutic delivery, protein production, and cell-based microarrays. In 2022, therapeutic delivery accounted for the largest share and is expected to achieve the highest CAGR during the projected period. The rising rate of chronic and immunological diseases is promoting the demand for cell therapies, resulting to drive the segment growth. Furthermore, growing research in the field of biotechnology and life sciences for the development of innovative therapeutics is propelling the segment growth in market.

North America accounted for the largest share in transfection technologies industry in 2022.

Transfection  Technologies Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Geographically, the transfection technologies market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the dominant share followed by Europe. The growing investments and fundings for the development of advanced therapies are propelling the growth of market in North America region. North America region focuses on research targeted towards development of cell-based therapies. Thus, increasing focus on advancement of research activities is promoting the growth of market. In addition, the booming healthcare sector in the region is anticipated to support the market growth.

Key players in the global transfection technologies market include Thermo Fisher Scientific Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), Merck KGaA (Germany), Sartorius AG (Polyplus) (Germany), Lonza (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Agilent Technologies, Inc. (US), MaxCyte (US), Revvity (US), Takara Bio Inc. (Japan), Promega Corporation (US), Danaher Corporation (US), BOC Sciences (US), RJH BIOSCIENCES (Canada), Synvolux (Netherlands), Altogen Biosciences (US), BioIVT (US), Incella GmbH (Germany), InvivoGen (France), Phoreus Biotech (US), STEMCELL Technologies (Canada), EZ Biosystems (US), OZ Biosciences (France), chemicell GmbH (Germany).

Scope of the Transfection Technologies Industry

Report Metric

Details

Market Revenue in 2023

$1.2 Billion

Projected Revenue by 2028

$1.8 Billion

Revenue Rate

Poised to Grow at a CAGR of 9.4%

Market Driver

Growing demand for cell & gene therapy

Market Opportunity

Increasing focus on personalized medicine

This report categorizes the transfection technologies market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • Kits & Reagents
  • Equipment

By Method

  • Physical Transfection
    • Electroporation
    • Biolistic Technology/Gene Gun
    • Microinjection
    • Other Physical Transfection Methods
  • Biochemical Based Transfection
    • Lipofection (Lipid-mediated Transfection)
    • Calcium Phosphate
    • Cationic Polymers
    • DEAE-Dextran
    • Magnet Assisted Transfection (MATra)
    • Dendrimer-Mediated Transfection
  • Viral-Vector Based Transfection

By Application

  • Therapeutic Delivery
  • Biomedical Research
  • Protein Production
  • Cell Based microarrays

By End User

  • Pharmaceutical and Biotechnology Companies
  • CROs & CDMOs
  • Academic and Research Institutes
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America (RoLATAM)
  • Middle East & Africa
    • Middle East
      • GCC Countries
      • Rest of Middle East (RoME)
    • Africa

Recent Developments of Transfection Technologies Industry:

  • In April 2023, Thermo Fisher Scientific Inc. launched Neon NxT Electroporation system used for the enhancement of genome editing. The system is suitable for transfection of challenging cell lines.
  • In February 2022, Polyplus acquired e-Zyvec, a provider of DNA design and production services for tailor-made DNA vectors. The acquisition aims to expand the portfolio in DNA vector engineering.
  • In January 2021, Merck KGaA acquired AmpTec, mRNA contract development and manufacturing organization (CDMO) to expand mRNA capabilities for vaccines, treatments, and diagnostics.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 56)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 STUDY SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
           1.3.3 CURRENCY CONSIDERED
    1.4 STAKEHOLDERS 
    1.5 SUMMARY OF CHANGES 
    1.6 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 61)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 TRANSFECTION TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 3 TRANSFECTION TECHNOLOGIES INDUSTRY SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
                    FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
                    FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS, 2022
                    2.2.1.1 Insights from primaries
                                FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.2.2 TOP-DOWN APPROACH
                    FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 
          FIGURE 8 MARKET: CAGR PROJECTIONS
          FIGURE 9 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 10 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 LIMITATIONS 
    2.7 RISK ANALYSIS 
    2.8 RECESSION IMPACT ANALYSIS 
 
3 EXECUTIVE SUMMARY (Page No. - 73)
    FIGURE 11 TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 TRANSFECTION TECHNOLOGIES INDUSTRY, BY METHOD, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 MARKET: GEOGRAPHIC ANALYSIS
 
4 PREMIUM INSIGHTS (Page No. - 77)
    4.1 TRANSFECTION TECHNOLOGIES MARKET OVERVIEW 
          FIGURE 16 GROWING DEMAND FOR CELL AND GENE THERAPY TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: TRANSFECTION TECHNOLOGIES INDUSTRY, BY PRODUCT AND COUNTRY 
          FIGURE 17 KITS & REAGENTS HELD LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022
    4.3 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 18 INDIA TO REGISTER HIGHEST CAGR IN GLOBAL MARKET OVER FORECAST PERIOD
    4.4 MARKET SHARE, BY PRODUCT, 2022 
          FIGURE 19 KITS & REAGENTS HELD LARGEST SHARE OF PRODUCTS MARKET IN 2022
 
5 MARKET OVERVIEW (Page No. - 80)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 20 TRANSFECTION TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 1 TRANSFECTION TECHNOLOGIES INDUSTRY: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing demand for cell and gene therapy
                                FIGURE 21 ESTIMATED CANCER CASELOAD, BY REGION
                                FIGURE 22 COMPARATIVE DATA FOR TOTAL NUMBER OF CLINICAL TRIALS
                    5.2.1.2 Rising research activity and R&D funding
                    5.2.1.3 Alliances for developing advanced therapeutic products
                    5.2.1.4 Expanded applications of transfection technologies
                    5.2.1.5 Technological advancements
           5.2.2 RESTRAINTS
                    5.2.2.1 Limited efficiency of transfection methods
                    5.2.2.2 High cost of transfection products
                    5.2.2.3 Adoption of alternative methods
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Rising focus on personalized medicines
                    5.2.3.2 Growth opportunities in emerging economies
           5.2.4 CHALLENGES
                    5.2.4.1 Concern related to cytotoxicity and transfection in hard-to-transfect cells
                    5.2.4.2 Challenges associated with large-scale transfection processes
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 2 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 INTENSITY OF COMPETITIVE RIVALRY
    5.4 ECOSYSTEM/MARKET MAP 
          FIGURE 23 MARKET: ECOSYSTEM
           5.4.1 PRODUCT VENDORS
                    TABLE 3 MARKET: PRODUCT VENDORS
           5.4.2 END USERS
                    TABLE 4 MARKET: END USERS
           5.4.3 REGULATORY BODIES
                    TABLE 5 MARKET: REGULATORY BODIES
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 24 MARKET: SUPPLY CHAIN ANALYSIS
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 25 VALUE CHAIN ANALYSIS OF MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
    5.7 REGULATORY LANDSCAPE 
           5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 9 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.8 PRICING ANALYSIS 
          TABLE 10 AVERAGE SELLING PRICE, BY COMPANY, 2022
          TABLE 11 AVERAGE SELLING PRICE, BY REGION
    5.9 TECHNOLOGY ANALYSIS 
          TABLE 12 MARKET: PROMINENT TECHNOLOGIES AND THEIR IMPACTS
    5.10 PATENT ANALYSIS 
           FIGURE 26 PATENT APPLICATIONS FOR MARKET, JANUARY 2013–OCTOBER 2023
           TABLE 13 MARKET: INDICATIVE LIST OF PATENTS
    5.11 KEY CONFERENCES AND EVENTS, 2024–2025 
           TABLE 14 MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2024–2025
    5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
           FIGURE 27 REVENUE SHIFT AND NEW POCKETS FOR TRANSFECTION PRODUCT PROVIDERS
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TRANSFECTION PRODUCTS
           5.13.2 BUYING CRITERIA FOR TRANSFECTION PRODUCTS
                     FIGURE 29 KEY BUYING CRITERIA FOR END USERS
                     TABLE 15 KEY BUYING CRITERIA FOR END USERS
 
6 TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT (Page No. - 107)
    6.1 INTRODUCTION 
          TABLE 16 TRANSFECTION TECHNOLOGIES INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 KITS & REAGENTS 
           6.2.1 KITS & REAGENTS SEGMENT TO HOLD LARGEST SHARE OF PRODUCTS MARKET
                    TABLE 17 TRANSFECTION KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 18 NORTH AMERICA: TRANSFECTION KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 19 EUROPE: TRANSFECTION KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 20 ASIA PACIFIC: TRANSFECTION KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 21 LATIN AMERICA: TRANSFECTION KITS & REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 22 MIDDLE EAST & AFRICA: TRANSFECTION KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 23 MIDDLE EAST: TRANSFECTION KITS & REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.3 EQUIPMENT 
           6.3.1 TECHNOLOGICAL DEVELOPMENTS AND RISING ADOPTION OF INNOVATIVE PRODUCTS TO BOOST MARKET GROWTH
                    TABLE 24 TRANSFECTION EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 25 NORTH AMERICA: TRANSFECTION EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 EUROPE: TRANSFECTION EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 27 ASIA PACIFIC: TRANSFECTION EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 28 LATIN AMERICA: TRANSFECTION EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 29 MIDDLE EAST & AFRICA: TRANSFECTION EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 30 MIDDLE EAST: TRANSFECTION EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION)
 
7 TRANSFECTION TECHNOLOGIES MARKET, BY METHOD (Page No. - 115)
    7.1 INTRODUCTION 
          TABLE 31 TRANSFECTION TECHNOLOGIES INDUSTRY, BY METHOD, 2021–2028 (USD MILLION)
    7.2 PHYSICAL TRANSFECTION 
          TABLE 32 PHYSICAL TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 33 NORTH AMERICA: PHYSICAL TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 34 EUROPE: PHYSICAL TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 35 ASIA PACIFIC: PHYSICAL TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 36 LATIN AMERICA: PHYSICAL TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 37 MIDDLE EAST & AFRICA: PHYSICAL TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 38 MIDDLE EAST: PHYSICAL TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 39 PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
           7.2.1 ELECTROPORATION
                    7.2.1.1 Growing demand for efficient cell transfection technologies to drive growth
                                TABLE 40 ELECTROPORATION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 41 NORTH AMERICA: ELECTROPORATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 42 EUROPE: ELECTROPORATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 43 ASIA PACIFIC: ELECTROPORATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 44 LATIN AMERICA: ELECTROPORATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 45 MIDDLE EAST & AFRICA: ELECTROPORATION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 46 MIDDLE EAST: ELECTROPORATION MARKET, BY REGION, 2021–2028 (USD MILLION)
           7.2.2 BIOLISTIC TRANSFECTION/GENE GUNS
                    7.2.2.1 Increasing focus on rapid and simple techniques to support market growth
                                TABLE 47 BIOLISTIC TRANSFECTION/GENE GUNS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 48 NORTH AMERICA: BIOLISTIC TRANSFECTION/GENE GUNS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 49 EUROPE: BIOLISTIC TRANSFECTION/GENE GUNS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 50 ASIA PACIFIC: BIOLISTIC TRANSFECTION/GENE GUNS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 51 LATIN AMERICA: BIOLISTIC TRANSFECTION/GENE GUNS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 52 MIDDLE EAST & AFRICA: BIOLISTIC TRANSFECTION/GENE GUNS MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 53 MIDDLE EAST: BIOLISTIC TRANSFECTION/GENE GUNS MARKET, BY REGION, 2021–2028 (USD MILLION)
           7.2.3 MICROINJECTION
                    7.2.3.1 Rising need for advanced cell transfection techniques to drive adoption
                                TABLE 54 MICROINJECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 55 NORTH AMERICA: MICROINJECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 56 EUROPE: MICROINJECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 57 ASIA PACIFIC: MICROINJECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 58 LATIN AMERICA: MICROINJECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 59 MIDDLE EAST & AFRICA: MICROINJECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 60 MIDDLE EAST: MICROINJECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
           7.2.4 OTHER PHYSICAL TRANSFECTION METHODS
                    TABLE 61 OTHER PHYSICAL TRANSFECTION METHODS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 62 NORTH AMERICA: OTHER PHYSICAL TRANSFECTION METHODS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 EUROPE: OTHER PHYSICAL TRANSFECTION METHODS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 ASIA PACIFIC: OTHER PHYSICAL TRANSFECTION METHODS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 65 LATIN AMERICA: OTHER PHYSICAL TRANSFECTION METHODS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 66 MIDDLE EAST & AFRICA: OTHER PHYSICAL TRANSFECTION METHODS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 67 MIDDLE EAST: OTHER PHYSICAL TRANSFECTION METHODS MARKET, BY REGION, 2021–2028 (USD MILLION)
    7.3 BIOCHEMICAL-BASED TRANSFECTION 
          TABLE 68 BIOCHEMICAL-BASED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 69 NORTH AMERICA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 70 EUROPE: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 71 ASIA PACIFIC: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 72 LATIN AMERICA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 73 MIDDLE EAST & AFRICA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 74 MIDDLE EAST: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 75 BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
           7.3.1 LIPOFECTION
                    7.3.1.1 High efficiency and compatibility to drive adoption
                                TABLE 76 LIPOFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 77 NORTH AMERICA: LIPOFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 78 EUROPE: LIPOFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 79 ASIA PACIFIC: LIPOFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 80 LATIN AMERICA: LIPOFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 81 MIDDLE EAST & AFRICA: LIPOFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 82 MIDDLE EAST: LIPOFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
           7.3.2 CALCIUM PHOSPHATE TRANSFECTION
                    7.3.2.1 Increasing R&D in cell-based therapies to drive market
                                TABLE 83 CALCIUM PHOSPHATE TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 84 NORTH AMERICA: CALCIUM PHOSPHATE TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 85 EUROPE: CALCIUM PHOSPHATE TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 86 ASIA PACIFIC: CALCIUM PHOSPHATE TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 87 LATIN AMERICA: CALCIUM PHOSPHATE TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 88 MIDDLE EAST & AFRICA: CALCIUM PHOSPHATE TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 89 MIDDLE EAST: CALCIUM PHOSPHATE TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
           7.3.3 CATIONIC POLYMER TRANSFECTION
                    7.3.3.1 Adoption of innovative biochemical materials for transfection to accelerate growth
                                TABLE 90 CATIONIC POLYMER TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 91 NORTH AMERICA: CATIONIC POLYMER TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 92 EUROPE: CATIONIC POLYMER TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 93 ASIA PACIFIC: CATIONIC POLYMER TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 94 LATIN AMERICA: CATIONIC POLYMER TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 95 MIDDLE EAST & AFRICA: CATIONIC POLYMER TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 96 MIDDLE EAST: CATIONIC POLYMER TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
           7.3.4 DEAE-DEXTRAN TRANSFECTION
                    7.3.4.1 Simplicity, rapidity, and cost-effectiveness to support adoption
                                TABLE 97 DEAE-DEXTRAN TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 98 NORTH AMERICA: DEAE-DEXTRAN TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 99 EUROPE: DEAE-DEXTRAN TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 100 ASIA PACIFIC: DEAE-DEXTRAN TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 101 LATIN AMERICA: DEAE-DEXTRAN TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 102 MIDDLE EAST & AFRICA: DEAE-DEXTRAN TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 103 MIDDLE EAST: DEAE-DEXTRAN TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
           7.3.5 MAGNET-ASSISTED TRANSFECTION
                    7.3.5.1 Rising emphasis on innovative therapies for genetic disorders to drive adoption
                                TABLE 104 MAGNET-ASSISTED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 105 NORTH AMERICA: MAGNET-ASSISTED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 106 EUROPE: MAGNET-ASSISTED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 107 ASIA PACIFIC: MAGNET-ASSISTED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 108 LATIN AMERICA: MAGNET-ASSISTED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 109 MIDDLE EAST & AFRICA: MAGNET-ASSISTED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 110 MIDDLE EAST: MAGNET-ASSISTED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
           7.3.6 DENDRIMER-MEDIATED TRANSFECTION
                    7.3.6.1 Non-biodegradable properties to restrain market growth
                                TABLE 111 DENDRIMER-MEDIATED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 112 NORTH AMERICA: DENDRIMER-MEDIATED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 113 EUROPE: DENDRIMER-MEDIATED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 114 ASIA PACIFIC: DENDRIMER-MEDIATED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 115 LATIN AMERICA: DENDRIMER-MEDIATED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 116 MIDDLE EAST & AFRICA: DENDRIMER-MEDIATED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 117 MIDDLE EAST: DENDRIMER-MEDIATED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
    7.4 VIRAL-VECTOR BASED TRANSFECTION 
           7.4.1 TECHNOLOGICAL DEVELOPMENTS AND GROWING NEED FOR CELL & GENE THERAPY TO DRIVE MARKET
                    TABLE 118 VIRAL VECTOR-BASED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 119 NORTH AMERICA: VIRAL VECTOR-BASED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 120 EUROPE: VIRAL VECTOR-BASED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 121 ASIA PACIFIC: VIRAL VECTOR-BASED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 122 LATIN AMERICA: VIRAL VECTOR-BASED TRANSFECTION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 123 MIDDLE EAST & AFRICA: VIRAL VECTOR-BASED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 124 MIDDLE EAST: VIRAL VECTOR-BASED TRANSFECTION MARKET, BY REGION, 2021–2028 (USD MILLION)
 
8 TRANSFECTION TECHNOLOGIES MARKET, BY APPLICATION (Page No. - 160)
    8.1 INTRODUCTION 
          TABLE 125 TRANSFECTION TECHNOLOGIES INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 THERAPEUTIC DELIVERY 
          TABLE 126 TRANSFECTION TECHNOLOGIES MARKET FOR THERAPEUTIC DELIVERY, BY REGION, 2021–2028 (USD MILLION)
          TABLE 127 NORTH AMERICA: MARKET FOR THERAPEUTIC DELIVERY, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 128 EUROPE: MARKET FOR THERAPEUTIC DELIVERY, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 129 ASIA PACIFIC: MARKET FOR THERAPEUTIC DELIVERY, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 130 LATIN AMERICA: MARKET FOR THERAPEUTIC DELIVERY, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 131 MIDDLE EAST & AFRICA: MARKET FOR THERAPEUTIC DELIVERY, BY REGION, 2021–2028 (USD MILLION)
          TABLE 132 MIDDLE EAST: MARKET FOR THERAPEUTIC DELIVERY, BY REGION, 2021–2028 (USD MILLION)
          TABLE 133 TRANSFECTION TECHNOLOGIES MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
           8.2.1 BIOTHERAPEUTICS
                    8.2.1.1 Rising need for cell and gene therapy to promote growth
                                TABLE 134 TRANSFECTION TECHNOLOGIES MARKET FOR BIOTHERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 135 NORTH AMERICA: MARKET FOR BIOTHERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 136 EUROPE: MARKET FOR BIOTHERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 137 ASIA PACIFIC: MARKET FOR BIOTHERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 138 LATIN AMERICA: MARKET FOR BIOTHERAPEUTICS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 139 MIDDLE EAST & AFRICA: MARKET FOR BIOTHERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 140 MIDDLE EAST: MARKET FOR BIOTHERAPEUTICS, BY REGION, 2021–2028 (USD MILLION)
           8.2.2 ELECTROIMMUNOTHERAPY
                    8.2.2.1 Increasing rate of chronic and immunological diseases to accelerate market growth
                                TABLE 141 TRANSFECTION TECHNOLOGIES MARKET FOR ELECTROIMMUNOTHERAPY, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 142 NORTH AMERICA: MARKET FOR ELECTROIMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 143 EUROPE: MARKET FOR ELECTROIMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 144 ASIA PACIFIC: MARKET FOR ELECTROIMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 145 LATIN AMERICA: MARKET FOR ELECTROIMMUNOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 146 MIDDLE EAST & AFRICA: MARKET FOR ELECTROIMMUNOTHERAPY, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 147 MIDDLE EAST: MARKET FOR ELECTROIMMUNOTHERAPY, BY REGION, 2021–2028 (USD MILLION)
           8.2.3 ELECTROCHEMOTHERAPY
                    8.2.3.1 Need for advanced chemotherapy due to rising cancer incidence to drive market
                                TABLE 148 TRANSFECTION TECHNOLOGIES MARKET FOR ELECTROCHEMOTHERAPY, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 149 NORTH AMERICA: MARKET FOR ELECTROCHEMOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 150 EUROPE: MARKET FOR ELECTROCHEMOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 151 ASIA PACIFIC: MARKET FOR ELECTROCHEMOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 152 LATIN AMERICA: MARKET FOR ELECTROCHEMOTHERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 153 MIDDLE EAST & AFRICA: MARKET FOR ELECTROCHEMOTHERAPY, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 154 MIDDLE EAST: MARKET FOR ELECTROCHEMOTHERAPY, BY REGION, 2021–2028 (USD MILLION)
    8.3 BIOMEDICAL RESEARCH 
          TABLE 155 TRANSFECTION TECHNOLOGIES MARKET FOR BIOMEDICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION)
          TABLE 156 NORTH AMERICA: MARKET FOR BIOMEDICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 157 EUROPE: MARKET FOR BIOMEDICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 158 ASIA PACIFIC: MARKET FOR BIOMEDICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 159 LATIN AMERICA: MARKET FOR BIOMEDICAL RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 160 MIDDLE EAST & AFRICA: MARKET FOR BIOMEDICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION)
          TABLE 161 MIDDLE EAST: MARKET FOR BIOMEDICAL RESEARCH, BY REGION, 2021–2028 (USD MILLION)
          TABLE 162 TRANSFECTION TECHNOLOGIES MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
           8.3.1 GENE & PROTEIN EXPRESSION STUDIES
                    8.3.1.1 Efforts to develop advanced gene therapy and genomic medicine promote growth
                                TABLE 163 TRANSFECTION TECHNOLOGIES MARKET FOR GENE & PROTEIN EXPRESSION STUDIES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 164 NORTH AMERICA: MARKET FOR GENE & PROTEIN EXPRESSION STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 165 EUROPE: MARKET FOR GENE & PROTEIN EXPRESSION STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 166 ASIA PACIFIC: MARKET FOR GENE & PROTEIN EXPRESSION STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 167 LATIN AMERICA: MARKET FOR GENE & PROTEIN EXPRESSION STUDIES, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 168 MIDDLE EAST & AFRICA: MARKET FOR GENE & PROTEIN EXPRESSION STUDIES, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 169 MIDDLE EAST: MARKET FOR GENE & PROTEIN EXPRESSION STUDIES, BY REGION, 2021–2028 (USD MILLION)
           8.3.2 CANCER RESEARCH
                    8.3.2.1 Increasing prevalence of cancer to propel market growth
                                TABLE 170 TRANSFECTION TECHNOLOGIES MARKET FOR CANCER RESEARCH, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 171 NORTH AMERICA: MARKET FOR CANCER RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 172 EUROPE: MARKET FOR CANCER RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 173 ASIA PACIFIC: MARKET FOR CANCER RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 174 LATIN AMERICA: MARKET FOR CANCER RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 175 MIDDLE EAST & AFRICA: MARKET FOR CANCER RESEARCH, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 176 MIDDLE EAST: MARKET FOR CANCER RESEARCH, BY REGION, 2021–2028 (USD MILLION)
           8.3.3 TRANSGENIC MODELS
                    8.3.3.1 Growing R&D activities and clinical studies to drive market
                                TABLE 177 TRANSFECTION TECHNOLOGIES MARKET FOR TRANSGENIC MODELS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 178 NORTH AMERICA: MARKET FOR TRANSGENIC MODELS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 179 EUROPE: MARKET FOR TRANSGENIC MODELS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 180 ASIA PACIFIC: MARKET FOR TRANSGENIC MODELS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 181 LATIN AMERICA: MARKET FOR TRANSGENIC MODELS, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 182 MIDDLE EAST & AFRICA: MARKET FOR TRANSGENIC MODELS, BY REGION, 2021–2028 (USD MILLION)
                                TABLE 183 MIDDLE EAST: MARKET FOR TRANSGENIC MODELS, BY REGION, 2021–2028 (USD MILLION)
    8.4 PROTEIN PRODUCTION 
           8.4.1 INCREASING INCIDENCE OF CHRONIC DISEASES AND DEMAND FOR PROTEIN THERAPEUTICS TO PROMOTE GROWTH
                    TABLE 184 TRANSFECTION TECHNOLOGIES MARKET FOR PROTEIN PRODUCTION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 185 NORTH AMERICA: MARKET FOR PROTEIN PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 186 EUROPE: MARKET FOR PROTEIN PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 187 ASIA PACIFIC: MARKET FOR PROTEIN PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 188 LATIN AMERICA: MARKET FOR PROTEIN PRODUCTION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 189 MIDDLE EAST & AFRICA: MARKET FOR PROTEIN PRODUCTION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 190 MIDDLE EAST: MARKET FOR PROTEIN PRODUCTION, BY REGION, 2021–2028 (USD MILLION)
    8.5 CELL-BASED MICROARRAYS 
           8.5.1 INCREASING NEED FOR CELL-BASED THERAPIES TO DRIVE MARKET
                    TABLE 191 TRANSFECTION TECHNOLOGIES MARKET FOR CELL-BASED MICROARRAYS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 192 NORTH AMERICA: MARKET FOR CELL-BASED MICROARRAYS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 193 EUROPE: MARKET FOR CELL-BASED MICROARRAYS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 194 ASIA PACIFIC: MARKET FOR CELL-BASED MICROARRAYS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 195 LATIN AMERICA: MARKET FOR CELL-BASED MICROARRAYS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 196 MIDDLE EAST & AFRICA: MARKET FOR CELL-BASED MICROARRAYS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 197 MIDDLE EAST: MARKET FOR CELL-BASED MICROARRAYS, BY REGION, 2021–2028 (USD MILLION)
 
9 TRANSFECTION TECHNOLOGIES MARKET, BY END USER (Page No. - 195)
    9.1 INTRODUCTION 
          TABLE 198 TRANSFECTION TECHNOLOGIES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE END-USER MARKET
                    TABLE 199 TRANSFECTION TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 200 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 201 EUROPE: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 202 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 203 LATIN AMERICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 204 MIDDLE EAST & AFRICA: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 205 MIDDLE EAST: MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
    9.3 CROS & CDMOS 
           9.3.1 CONTRACT RESEARCH AND MANUFACTURING SECTOR TO SEE STRONG GROWTH
                    TABLE 206 TRANSFECTION TECHNOLOGIES MARKET FOR CROS & CDMOS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 207 NORTH AMERICA: MARKET FOR CROS & CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 208 EUROPE: MARKET FOR CROS & CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 209 ASIA PACIFIC: MARKET FOR CROS & CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 210 LATIN AMERICA: MARKET FOR CROS & CDMOS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 211 MIDDLE EAST & AFRICA: MARKET FOR CROS & CDMOS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 212 MIDDLE EAST: MARKET FOR CROS & CDMOS, BY REGION, 2021–2028 (USD MILLION)
    9.4 ACADEMIC & RESEARCH INSTITUTES 
           9.4.1 INCREASING R&D AND GROWING TREND OF COLLABORATIVE RESEARCH TO PROMOTE MARKET GROWTH
                    TABLE 213 TRANSFECTION TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 214 NORTH AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 215 EUROPE: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 216 ASIA PACIFIC: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 217 LATIN AMERICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 218 MIDDLE EAST & AFRICA: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 219 MIDDLE EAST: MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
    9.5 OTHER END USERS 
          TABLE 220 TRANSFECTION TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 221 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 222 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 223 ASIA PACIFIC: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 224 LATIN AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 225 MIDDLE EAST & AFRICA: MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 226 MIDDLE EAST: MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
 
10 TRANSFECTION TECHNOLOGIES MARKET, BY REGION (Page No. - 210)
     10.1 INTRODUCTION 
             TABLE 227 TRANSFECTION TECHNOLOGIES INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 30 NORTH AMERICA: TRANSFECTION TECHNOLOGIES MARKET SNAPSHOT
                        TABLE 228 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 229 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 230 NORTH AMERICA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                        TABLE 231 NORTH AMERICA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 232 NORTH AMERICA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 233 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 234 NORTH AMERICA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 235 NORTH AMERICA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 236 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 US
                        10.2.2.1 US to dominate North American market
                                      TABLE 237 US: INDICATIVE LIST OF THERAPIES APPROVED IN 2022
                                      TABLE 238 US: INDICATIVE LIST OF PRODUCTS ANTICIPATED TO BE APPROVED IN 2023
                                      TABLE 239 US: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 240 US: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 241 US: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 242 US: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 243 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 244 US: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 245 US: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 246 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Rising investments in R&D to drive market
                                      TABLE 247 CANADA: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 248 CANADA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 249 CANADA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 250 CANADA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 251 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 252 CANADA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 253 CANADA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 254 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             TABLE 255 EUROPE: INDICATIVE LIST OF THERAPIES APPROVED IN 2022
             TABLE 256 EUROPE: INDICATIVE LIST OF PRODUCTS ANTICIPATED TO BE APPROVED IN 2023
             10.3.1 EUROPE: RECESSION IMPACT
                        TABLE 257 EUROPE: TRANSFECTION TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 258 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 259 EUROPE: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                        TABLE 260 EUROPE: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 261 EUROPE: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 262 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 263 EUROPE: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 264 EUROPE: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 265 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Germany to hold largest share of European market till 2028
                                      TABLE 266 GERMANY: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 267 GERMANY: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 268 GERMANY: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 269 GERMANY: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 270 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 271 GERMANY: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 272 GERMANY: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 273 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Increasing government funding for genomic projects to drive market
                                      TABLE 274 UK: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 275 UK: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 276 UK: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 277 UK: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 278 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 279 UK: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 280 UK: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 281 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Focus on collaborative development of advanced cell and gene therapies to promote market growth
                                      TABLE 282 FRANCE: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 283 FRANCE: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 284 FRANCE: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 285 FRANCE: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 286 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 287 FRANCE: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 288 FRANCE: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 289 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Rising R&D investments and growing biotech industry to drive market
                                      TABLE 290 ITALY: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 291 ITALY: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 292 ITALY: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 293 ITALY: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 294 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 295 ITALY: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 296 ITALY: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 297 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Growing expansion of research centers to stimulate market growth
                                      TABLE 298 SPAIN: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 299 SPAIN: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 300 SPAIN: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 301 SPAIN: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 302 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 303 SPAIN: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 304 SPAIN: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 305 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 306 REST OF EUROPE: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 307 REST OF EUROPE: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                        TABLE 308 REST OF EUROPE: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 309 REST OF EUROPE: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 310 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 311 REST OF EUROPE: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 312 REST OF EUROPE: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 313 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
                        FIGURE 31 ASIA PACIFIC: TRANSFECTION TECHNOLOGIES MARKET SNAPSHOT
                        TABLE 314 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 315 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 316 ASIA PACIFIC: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                        TABLE 317 ASIA PACIFIC: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 318 ASIA PACIFIC: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 319 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 320 ASIA PACIFIC: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 321 ASIA PACIFIC: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 322 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Increasing R&D expenditure to propel market growth
                                      TABLE 323 CHINA: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 324 CHINA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 325 CHINA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 326 CHINA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 327 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 328 CHINA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 329 CHINA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 330 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 JAPAN
                        10.4.3.1 Booming CGT & RM sector to drive market
                                      TABLE 331 JAPAN: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 332 JAPAN: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 333 JAPAN: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 334 JAPAN: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 335 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 336 JAPAN: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 337 JAPAN: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 338 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 SOUTH KOREA
                        10.4.4.1 Alliances and investments in research to drive market
                                      TABLE 339 SOUTH KOREA: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 340 SOUTH KOREA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 341 SOUTH KOREA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 342 SOUTH KOREA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 343 SOUTH KOREA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 344 SOUTH KOREA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 345 SOUTH KOREA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 346 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 INDIA
                        10.4.5.1 Growing demand for advanced treatment solutions to propel market growth
                                      TABLE 347 INDIA: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 348 INDIA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 349 INDIA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 350 INDIA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 351 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 352 INDIA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 353 INDIA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 354 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.6 AUSTRALIA
                        10.4.6.1 Rising prevalence of chronic diseases and growing life science sector to drive market
                                      TABLE 355 AUSTRALIA: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 356 AUSTRALIA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 357 AUSTRALIA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 358 AUSTRALIA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 359 AUSTRALIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 360 AUSTRALIA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 361 AUSTRALIA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 362 AUSTRALIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.7 REST OF ASIA PACIFIC
                        TABLE 363 REST OF ASIA PACIFIC: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 364 REST OF ASIA PACIFIC: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                        TABLE 365 REST OF ASIA PACIFIC: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 366 REST OF ASIA PACIFIC: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 367 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 368 REST OF ASIA PACIFIC: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 369 REST OF ASIA PACIFIC: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 370 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 371 LATIN AMERICA: TRANSFECTION TECHNOLOGIES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 372 LATIN AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 373 LATIN AMERICA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                        TABLE 374 LATIN AMERICA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 375 LATIN AMERICA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 376 LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 377 LATIN AMERICA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 378 LATIN AMERICA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 379 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.2 BRAZIL
                        10.5.2.1 Brazil to hold largest share of LATAM market
                                      TABLE 380 BRAZIL: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 381 BRAZIL: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 382 BRAZIL: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 383 BRAZIL: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 384 BRAZIL: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 385 BRAZIL: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 386 BRAZIL: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 387 BRAZIL: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.3 MEXICO
                        10.5.3.1 Rising research activity to support market growth
                                      TABLE 388 MEXICO: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 389 MEXICO: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 390 MEXICO: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 391 MEXICO: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 392 MEXICO: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 393 MEXICO: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 394 MEXICO: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 395 MEXICO: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.4 ARGENTINA
                        10.5.4.1 Increasing government initiatives to drive market
                                      TABLE 396 ARGENTINA: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 397 ARGENTINA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 398 ARGENTINA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 399 ARGENTINA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 400 ARGENTINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 401 ARGENTINA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 402 ARGENTINA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 403 ARGENTINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.5 REST OF LATIN AMERICA
                        TABLE 404 REST OF LATIN AMERICA: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 405 REST OF LATIN AMERICA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                        TABLE 406 REST OF LATIN AMERICA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 407 REST OF LATIN AMERICA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 408 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 409 REST OF LATIN AMERICA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 410 REST OF LATIN AMERICA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 411 REST OF LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
                        TABLE 412 MIDDLE EAST & AFRICA: TRANSFECTION TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 413 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 414 MIDDLE EAST & AFRICA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                        TABLE 415 MIDDLE EAST & AFRICA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 416 MIDDLE EAST & AFRICA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 417 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 418 MIDDLE EAST & AFRICA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 419 MIDDLE EAST & AFRICA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 420 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.6.2 MIDDLE EAST
                        TABLE 421 MIDDLE EAST: TRANSFECTION TECHNOLOGIES MARKET, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 422 MIDDLE EAST: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 423 MIDDLE EAST: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                        TABLE 424 MIDDLE EAST: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 425 MIDDLE EAST: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 426 MIDDLE EAST: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 427 MIDDLE EAST: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 428 MIDDLE EAST: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 429 MIDDLE EAST: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        10.6.2.1 GCC Countries
                                     10.6.2.1.1 Increasing collaborations and partnerships to advance cell therapy to drive market
                                                      TABLE 430 GCC COUNTRIES: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                                      TABLE 431 GCC COUNTRIES: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                                      TABLE 432 GCC COUNTRIES: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                                      TABLE 433 GCC COUNTRIES: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                                      TABLE 434 GCC COUNTRIES: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                                      TABLE 435 GCC COUNTRIES: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                                      TABLE 436 GCC COUNTRIES: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                                      TABLE 437 GCC COUNTRIES: MARKET, BY END USER, 2021–2028 (USD MILLION)
                        10.6.2.2 Rest of the Middle East
                                      TABLE 438 REST OF MIDDLE EAST: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 439 REST OF MIDDLE EAST: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 440 REST OF MIDDLE EAST: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 441 REST OF MIDDLE EAST: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 442 REST OF MIDDLE EAST: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 443 REST OF MIDDLE EAST: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 444 REST OF MIDDLE EAST: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 445 REST OF MIDDLE EAST: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.6.3 AFRICA
                        10.6.3.1 Rising prevalence of HIV and cancer and growing precision medicine initiatives to fuel market growth
                                      TABLE 446 AFRICA: TRANSFECTION TECHNOLOGIES MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 447 AFRICA: MARKET, BY METHOD, 2021–2028 (USD MILLION)
                                      TABLE 448 AFRICA: PHYSICAL TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 449 AFRICA: BIOCHEMICAL-BASED TRANSFECTION MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 450 AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 451 AFRICA: MARKET FOR THERAPEUTIC DELIVERY, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 452 AFRICA: MARKET FOR BIOMEDICAL RESEARCH, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 453 AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 319)
     11.1 OVERVIEW 
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
     11.3 REVENUE SHARE ANALYSIS 
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 34 TRANSFECTION TECHNOLOGIES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
             TABLE 454 TRANSFECTION TECHNOLOGIES INDUSTRY: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
             11.5.5 COMPANY FOOTPRINT
                        TABLE 455 COMPANY FOOTPRINT
                        TABLE 456 COMPANY PRODUCT FOOTPRINT
                        TABLE 457 COMPANY REGION FOOTPRINT
     11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 RESPONSIVE COMPANIES
             11.6.3 DYNAMIC COMPANIES
             11.6.4 STARTING BLOCKS
                        FIGURE 36 TRANSFECTION TECHNOLOGIES INDUSTRY: COMPANY EVALUATION MATRIX (STARTUPS/SMES) (2022)
             11.6.5 COMPETITIVE BENCHMARKING
                        TABLE 458 TRANSFECTION TECHNOLOGIES INDUSTRY: KEY STARTUPS/SMES
                        TABLE 459 TRANSFECTION TECHNOLOGIES INDUSTRY: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
     11.7 COMPETITIVE SCENARIO 
             11.7.1 PRODUCT LAUNCHES
                        TABLE 460 TRANSFECTION TECHNOLOGIES INDUSTRY: KEY PRODUCT LAUNCHES, JANUARY 2020−DECEMBER 2023
             11.7.2 DEALS
                        TABLE 461 TRANSFECTION TECHNOLOGIES INDUSTRY: KEY DEALS, JANUARY 2020− DECEMBER 2023
             11.7.3 OTHER DEVELOPMENTS
                        TABLE 462 TRANSFECTION TECHNOLOGIES INDUSTRY: OTHER DEVELOPMENTS, JANUARY 2020−NOVEMBER 2023
 
12 COMPANY PROFILES (Page No. - 333)
     12.1 KEY PLAYERS 
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
             12.1.1 THERMO FISHER SCIENTIFIC INC.
                        TABLE 463 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
                        TABLE 464 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
                        TABLE 465 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES
                        TABLE 466 THERMO FISHER SCIENTIFIC INC.: DEALS
                        TABLE 467 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS
             12.1.2 BIO-RAD LABORATORIES, INC.
                        TABLE 468 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 38 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 469 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
             12.1.3 QIAGEN
                        TABLE 470 QIAGEN: BUSINESS OVERVIEW
                        FIGURE 39 QIAGEN: COMPANY SNAPSHOT (2022)
                        TABLE 471 QIAGEN: PRODUCTS OFFERED
             12.1.4 MERCK KGAA
                        TABLE 472 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2022)
                        TABLE 473 MERCK KGAA: PRODUCTS OFFERED
                        TABLE 474 MERCK KGAA: DEALS
                        TABLE 475 MERCK KGAA: OTHER DEVELOPMENTS
             12.1.5 SARTORIUS AG (POLYPLUS)
                        TABLE 476 SARTORIUS AG (POLYPLUS): BUSINESS OVERVIEW
                        FIGURE 41 SARTORIUS AG (POLYPLUS): COMPANY SNAPSHOT (2022)
                        TABLE 477 SARTORIUS AG (POLYPLUS): PRODUCTS OFFERED
                        TABLE 478 SARTORIUS AG (POLYPLUS): PRODUCT LAUNCHES
                        TABLE 479 SARTORIUS AG (POLYPLUS): DEALS
             12.1.6 LONZA
                        TABLE 480 LONZA: BUSINESS OVERVIEW
                        FIGURE 42 LONZA: COMPANY SNAPSHOT (2022)
                        TABLE 481 LONZA: PRODUCTS OFFERED
                        TABLE 482 LONZA: PRODUCT LAUNCHES
                        TABLE 483 LONZA: DEALS
             12.1.7 F. HOFFMANN-LA ROCHE LTD.
                        TABLE 484 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
                        FIGURE 43 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
                        TABLE 485 F. HOFFMAN-LA ROCHE LTD.: PRODUCTS OFFERED
             12.1.8 AGILENT TECHNOLOGIES, INC.
                        TABLE 486 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
                        FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 487 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
                        TABLE 488 AGILENT TECHNOLOGIES, INC.: DEALS
             12.1.9 MAXCYTE
                        TABLE 489 MAXCYTE: BUSINESS OVERVIEW
                        FIGURE 45 MAXCYTE: COMPANY SNAPSHOT (2022)
                        TABLE 490 MAXCYTE: PRODUCTS OFFERED
                        TABLE 491 MAXCYTE: PRODUCT LAUNCHES
                        TABLE 492 MAXCYTE: DEALS
             12.1.10 REVVITY
                        TABLE 493 REVVITY: BUSINESS OVERVIEW
                        FIGURE 46 REVVITY: COMPANY SNAPSHOT (2022)
                        TABLE 494 REVVITY: PRODUCTS OFFERED
                        TABLE 495 REVVITY: DEALS
                        TABLE 496 REVVITY: OTHER DEVELOPMENTS
             12.1.11 TAKARA BIO INC.
                        TABLE 497 TAKARA BIO INC.: BUSINESS OVERVIEW
                        FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT (2022)
                        TABLE 498 TAKARA BIO INC.: COMPANY OVERVIEW
             12.1.12 PROMEGA CORPORATION
                        TABLE 499 PROMEGA CORPORATION: BUSINESS OVERVIEW
                        TABLE 500 PROMEGA CORPORATION: PRODUCTS OFFERED
             12.1.13 DANAHER CORPORATION
                        TABLE 501 DANAHER CORPORATION: BUSINESS OVERVIEW
                        AFIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
                        TABLE 502 DANAHER CORPORATION: PRODUCTS OFFERED
                        TABLE 503 DANAHER CORPORATION: PRODUCT LAUNCHES
                        TABLE 504 DANAHER CORPORATION: DEALS
                        TABLE 505 DANAHER CORPORATION: OTHER DEVELOPMENTS
     12.2 OTHER PLAYERS 
             12.2.1 BOC SCIENCES
                        TABLE 506 BOC SCIENCES: COMPANY OVERVIEW
             12.2.2 RJH BIOSCIENCES
                        TABLE 507 RJH BIOSCIENCES: COMPANY OVERVIEW
             12.2.3 SYNVOLUX
                        TABLE 508 SYNVOLUX: COMPANY OVERVIEW
             12.2.4 ALTOGEN BIOSYSTEMS
                        TABLE 509 ALTOGEN BIOSYSTEMS: COMPANY OVERVIEW
             12.2.5 BIOIVT
                        TABLE 510 BIOIVT: COMPANY OVERVIEW
             12.2.6 INCELLA GMBH
                        TABLE 511 INCELLA GMBH (SCREENFECT): COMPANY OVERVIEW
             12.2.7 INVIVOGEN
                        TABLE 512 INVIVOGEN: COMPANY OVERVIEW
             12.2.8 PHOREUS BIOTECH
                        TABLE 513 PHOREUS BIOTECH: COMPANY OVERVIEW
             12.2.9 STEMCELL TECHNOLOGIES
                        TABLE 514 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW
             12.2.10 EZ BIOSYSTEMS
                        TABLE 515 EZ BIOSYSTEMS: COMPANY OVERVIEW
             12.2.11 OZ BIOSCIENCES
                        TABLE 516 OZ BIOSCIENCES: COMPANY OVERVIEW
             12.2.12 CHEMICELL GMBH
                        TABLE 517 CHEMICELL GMBH: COMPANY OVERVIEW
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 390)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global transfection technologies market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the transfection technologies market. The secondary sources used for this study include US Food and Drug Administration (FDA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Organisation for Economic Co-operation and Development (OECD), Latin American Society for Developmental Biology, International Society for Cell & Gene Therapy (ISCT), American Society of Gene & Cell Therapy (ASGCT), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), South African Medical Research Council (SAMRC), National Institute for Health and Care Research (NIHR), International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), National Institutes of Health (NIH), European Commission, and European Pharmaceutical Review. Secondary sources include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements), business magazines, research journals, press releases, articles & blogs. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global transfection technologies market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biopharmaceutical companies, CROs, CDMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across five major regions, including the Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Transfection  Technologies Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the transfection technologies market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research.
  • The revenues generated from the transfection technologies business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Transfection  Technologies Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Transfection  Technologies Market Size, and Share

Data Triangulation

To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Transfection is the process of deliberately introducing naked or purified nucleic acids (including DNA, RNA, or proteins) into eukaryotic cells.  Transfection is a powerful tool that helps in the study of gene functions and can be achieved using biochemical, physical, and viral vector methods. Transfection technologies have been used in life science research and have been exploited for therapeutic delivery like gene therapy. This gene transfer technology enables the study of gene function and protein expression in a cellular environment.

The scope of the report includes FDA-approved transfection technologies products that are used for the transfection of nucleic acids into eukaryotic cells with the help of innovative method where the transfection technologies are intended to deliver DNA, RNA, or proteins for biomedical research, therapeutic delivery, and protein production.

Stakeholders

  • Transfection products manufacturing companies
  • Pharmaceutical & Biopharmaceutical Companies
  • Chemical Companies
  • Biopharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Research Institutes and Universities 
  • Venture Capitalists & Investors
  • Government Associations

Report Objectives

  • To define, describe, segment, and forecast the transfection technologies market by product type, method, application, end user, and region
  • To provide detailed information about the major factors (such as drivers, restraints, opportunities, and challenges) influencing the market growth
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the transfection technologies market in five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, along with their respective key countries
  • To profile the key players in the transfection technologies market and comprehensively analyze their core competencies2 and market shares
  • To track and analyze competitive developments, such as product launches, acquisitions, expansions, collaborations, agreements, and partnerships of the leading players in the transfection technologies market
  • To benchmark players within the transfection technologies market using the ‘Competitive Leadership Mapping’ framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share/rank

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Segment Analysis

  • Further breakdown of the other physical transfection method segments into laserfection and sonoporation.
  • Further breakdown of the other end users into hospitals and clinics.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Geographical Analysis

  • Further breakdown of the Rest of European transfection technologies market into countries
  • Further breakdown of the Rest of Asia Pacific transfection technologies market into countries
  • Further breakdown of the Rest of Latin American transfection technologies market into countries
  • Further breakdown of the Rest of Middle East transfection technologies market into countries
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 1355
Published ON
Feb, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Transfection Technologies Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback